Skip to main content
SpringerLink
Log in

Pneumococcal Vaccine Conjugate (Wyeth-Lederle)

PNCRM5, PNCRM7, PNCRM9

  • Section 2: Prophylactic Anti-Infective Vaccines
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Powers DC, Anderson EL, Lottenbach K, et al. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996 Apr; 173: 1014–8

    Article  PubMed  CAS  Google Scholar 

  2. King Jr JC, Vink PE, Farley JJ, et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996 Mar; 15: 192–6

    Article  PubMed  Google Scholar 

  3. Pichichero ME, Shelly MA, Treanor JJ. Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers. Pediatr Infect Dis J 1997 Jan; 16: 72–4

    Article  PubMed  CAS  Google Scholar 

  4. Prentice K. New flu and pneumococcal vaccines coming soon? Inpharma 1998 Oct 31; 1161: 9–10

    Article  Google Scholar 

  5. Ähman H, Käyhty H, Tamminen P, et al. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J 1996 Feb; 15: 134–9

    Article  PubMed  Google Scholar 

  6. King Jr JC, Vink PE, Farley JJ, et al. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics 1997 Apr; 99: 575–80

    Article  PubMed  Google Scholar 

  7. Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, et al. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis 1996 Jan; 173: 83–90

    Article  PubMed  CAS  Google Scholar 

  8. Musher DM, Groover JE, Watson DA, et al. IgG responses to protein-conjugated pneumococcal capsular polysaccharides in persons who are genetically incapable of responding to unconjugated polysaccharides. Clin Infect Dis 1998 Dec; 27: 1487–90

    Article  PubMed  CAS  Google Scholar 

  9. Rennels MB, Edwards KM, Keyserling HL, et al. Immunogenicity and safety of 7-valent pneumococcal-CRM197 conjugate vaccine. Pediatr Res 1996 Apr; 39 (Pt 2): 183

    Google Scholar 

  10. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998 Apr; 101 (4 Pt 1): 604–11

    Article  PubMed  CAS  Google Scholar 

  11. Strnad N, Reichenbach J, Trautwein M, et al. Significant opsonophagocytic activity after immunizationwith pneumococcal conjugate vaccine in patientswith polysaccharide-specific immunodeficiency. Clin Microbiol Infect 1999 Mar; 5 Suppl. 3: 349

    Google Scholar 

  12. Breukels MA, Rijkers GT, Voorhorst-Ogink MM, et al. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta. J Infect Dis 1999 May; 179: 1152–6

    Article  PubMed  CAS  Google Scholar 

  13. Barnett ED, Pelton SI, Cabral EJ, et al. Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children. Clin Infect Dis 1999 Jul; 29: 191–2

    Article  PubMed  CAS  Google Scholar 

  14. Dagan R, Givon N, Yagupsky P, et al. Effect of a 9-valent pneumococcal vaccine conjugated to CRM197 (PncCRM9) on nasopharyngeal carriage of vaccine type and non-vaccine type S. pneumoniae (Pnc) strains among day care center attendees. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego, 299

    Google Scholar 

  15. Black S, Shinefield H, Ray P, et al. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: results of the Northern California Kaiser Permanente Efficacy Trial [late-breaker abstracts]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego, 23

    Google Scholar 

  16. Wyeth Lederle pneumococcal vaccine cuts otitis media in children. Marketletter 1999 May 10; 26 (19): 19

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pneumococcal Vaccine Conjugate (Wyeth-Lederle). Drugs R&D 2, 215–219 (1999). https://doi.org/10.2165/00126839-199902030-00017

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902030-00017

Keywords

Search

Navigation